FORE Biotherapeutics has announced that two abstracts on its investigational therapy plixorafenib will be presented at the ...

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...

The Baton Rouge Area Foundation announced Monday that it will move to a new location late this summer.  BRAF has outgrown its current office space at 100 North Street and will move just blocks away to ...

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib ...

To fight this, doctors often use drugs called BRAF inhibitors, such as vemurafenib, which can stop the cancer’s growth—at ...

Patients undergoing BRAF/MEK inhibitor therapy for melanoma more commonly experience VKH-like uveitis compared with other malignancy types.

It will take about four months to build out the 17,708-square-foot space; the foundation expects to move in during August.

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

No writing assistance was utilized in the production of this manuscript. BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK ...

In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, which were presented at ASCO Gastrointestinal Cancers Symposium.